TVRD
Tvardi Therapeutics, Inc.
Nasdaq · CIK 1346830
Last close1.15
Daily change-0.09 (-7.26%)
10 Years gain-99.63%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
TVRD · STANDARD
SIC 2834 · Pharmaceutical Preparations · Fiscal year end 1231
Fundamental
13.2Momentum
n/aAcceleration
n/aConfidence
62.0Annual Revenue13
Quarterly Revenue44
Annual CFO10
Balance SheetMissing
RankingLimited
Score Breakdown
Growth0.0 / 25
Quality12.5 / 25
Capital Efficiency0.0 / 20
Balance Sheet0.0 / 15
Shareholder Economics0.0 / 10
Forward Indicators0.0 / 5
Signals
No positive signals calculated.
Key Metrics
Revenue Growth TTM-71.33%OK
Revenue CAGR 3Y-32.33%OK
Gross Marginn/aMISSING
Operating Marginn/aMISSING
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROICn/aMISSING
Incremental Operating Margin 3Yn/aNOT_MEANINGFUL
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Yn/aINSUFFICIENT_HISTORY
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | n/a | $0.00 | -$26.75M | -$23.50M | n/a | n/a | n/a | n/a | n/a | 7.78M |
| 2025 FY Dec 31, 2024 | n/a | $0.00 | -$28.11M | -$18.31M | n/a | n/a | n/a | n/a | n/a | 2.57M |
| 2024 FY Dec 31, 2024 | $7.14M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| 2024 FY Dec 31, 2023 | $20.97M | $20.97M | -$121.50M | -$92.08M | -$94.45M | 100% | -579.43% | -450.46% | n/a | 4.51M |
| 2024 FY Dec 31, 2022 | $41.87M | $41.87M | -$87.54M | -$78.73M | -$78.77M | 100% | -209.08% | -188.15% | n/a | 4.47M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $8.25M | sum latest 4 fiscal quarters Revenue | OK | 0001558370-25-007575, 0001558370-24-012231 |
| Revenue Growth TTM | -71.33% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001558370-25-007575, 0001558370-24-012231 |
| Revenue CAGR 3Y | -32.33% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001558370-25-002705 |
| Revenue CAGR 5Y | -18.53% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001558370-25-002705 |
| Gross Profit CAGR 3Y | n/a | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | INSUFFICIENT_HISTORY | derived |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | derived |
| SBC / FCF | n/a | SBC / FCF | NOT_MEANINGFUL | derived |
| Dividend Payout Ratio | n/a | Cash dividends paid / Net income | NOT_MEANINGFUL | derived |
| Diluted EPS TTM | n/a | Net income TTM / Diluted shares | NOT_MEANINGFUL | derived |
| Gross Margin Delta 1Y | n/a | GrossMargin_current - GrossMargin_prior_year | INSUFFICIENT_HISTORY | derived |
| Gross Margin Delta 3Y | n/a | GrossMargin_current - GrossMargin_3Y_ago | INSUFFICIENT_HISTORY | derived |
| Operating Margin Delta 1Y | n/a | OperatingMargin_current - OperatingMargin_prior_year | INSUFFICIENT_HISTORY | derived |